Copper Drug Clears Toxic Alzheimer’s Proteins and Restores Memory

Researchers at Monash University have found that a copper-based drug significantly reduces toxic protein accumulation in the brain and improves memory in laboratory models of Alzheimer’s disease. The compound, called Cu(ATSM), cleared 42 percent of amyloid-beta proteins while improving spatial learning by 44 percent over 56 days.

The mechanism works at the blood-brain barrier, the interface between the bloodstream and the brain. Alzheimer’s involves toxic proteins accumulating in the brain, but the brain’s waste-clearing systems fail to remove them efficiently. Cu(ATSM) repairs a critical waste-clearing pump that normally functions as the brain’s garbage disposal.

Researchers found that the drug increased P-gp clearance pumps at the blood-brain barrier by 24 percent, effectively restoring the brain’s ability to clear toxic proteins. The result was measurable improvement in memory and cognitive function in animal models.

What makes Cu(ATSM) attractive to researchers is its prior safety history. The compound has already been tested in humans for other neurological conditions, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS). This means human safety data already exists, potentially accelerating the path to Alzheimer’s trials.

The research was published in ACS Chemical Neuroscience on June 15, 2026. It represents one of many recent attempts to target the mechanisms behind Alzheimer’s rather than just treating symptoms.

Alzheimer’s remains one of the most common forms of dementia and a leading cause of death in elderly populations. Current drugs offer modest cognitive benefits but don’t slow underlying disease progression. Any drug that actually clears toxic proteins and improves memory would represent a genuine breakthrough.

The challenge ahead is moving from laboratory mice to human patients. Animal models don’t always predict human outcomes. But the safety history of the compound and the clarity of the mechanism offer hope that human trials could proceed relatively quickly if funding and institutional support align.